NASDAQ:TELO Telomir Pharmaceuticals 8/14/2025 Earnings Report $1.24 -0.01 (-0.40%) As of 02:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Telomir Pharmaceuticals EPS ResultsActual EPS-$0.17Consensus EPS -$0.08Beat/MissMissed by -$0.09One Year Ago EPSN/ATelomir Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATelomir Pharmaceuticals Announcement DetailsQuarterDate8/14/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsTelomir Pharmaceuticals' next earnings date is estimated for Tuesday, November 11, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Telomir Pharmaceuticals Earnings HeadlinesTelomir Pharmaceuticals Completes $2.9 Million Stock SaleSeptember 4 at 10:31 AM | tipranks.comHead to Head Survey: Telomir Pharmaceuticals (NASDAQ:TELO) & 4D Molecular Therapeutics (NASDAQ:FDMT)September 2 at 3:59 AM | americanbankingnews.comRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns just aren’t enough anymore. But what if you could reach your Freedom Number—the monthly income that makes retirement secure—using far less money than you thought possible? That’s exactly what Kelly G. discovered. She calls it “life-changing,” saying the income just keeps growing and that early retirement suddenly looks real. This strategy was once reserved for the ultra-wealthy, but it’s now available to everyday investors.September 5 at 2:00 AM | Investors Alley (Ad)Telomir stock soars after drug candidate shows promising epigenetic effectsAugust 28, 2025 | za.investing.comTELO Makes Progress Toward Human TrialsAugust 15, 2025 | msn.comTelomir Flat on Trial Data ReleaseAugust 7, 2025 | baystreet.caSee More Telomir Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Telomir Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Telomir Pharmaceuticals and other key companies, straight to your email. Email Address About Telomir PharmaceuticalsTelomir Pharmaceuticals (NASDAQ:TELO), a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.View Telomir Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Affirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 Outlook Upcoming Earnings Synopsys (9/9/2025)Oracle (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
